New drug duo targets rare, aggressive eye cancer
NCT ID NCT06121180
Summary
This study is testing whether combining two existing drugs, cemiplimab and Ziv-aflibercept, is safe and can help control metastatic uveal melanoma, a rare and aggressive cancer that starts in the eye. The goal is to see if this combination can shrink tumors or stop them from growing in up to 32 adults with this condition. This is a Phase 2 trial, meaning researchers are primarily looking for initial signs of effectiveness and safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Northwell Health Center for Advanced Medicine
RECRUITINGNew Hyde Park, New York, 11042, United States
Contact
-
The Angeles Clinic and Research Institute
RECRUITINGLos Angeles, California, 90025, United States
Contact
-
University of Chicago Medical Center
RECRUITINGChicago, Illinois, 60637, United States
Contact
Conditions
Explore the condition pages connected to this study.